Zion Med Pharma launches in Brazil the 1st Phytotherapeutic of Cannabis Sativa Extract with Full Spectrum CBD for Anxiety and Insomnia

Sponsored content by Zion Med Pharma

The National Health Surveillance Agency (Anvisa) granted, with publication in the official diary, the first authorization under RDC 327/19 for a natural plant extract of cannabis sativa with CBD (Cannabidiol) and THC (Tetrahydrocannabinol), without any psychoactive effect, various therapeutic indications, and permission for commercialization in Brazilian pharmacies.

The product was registered by the Brazilian company Zion Med Pharma and is being imported from Switzerland, where the highest standards of manufacturing and quality are practiced.

The extract contains, in its formula, a complete extraction of 200 mg/ml of phyto compounds and cannabinoids CBD (Cannabidiol at 50mg/ml), THC (Tetrahydrocannabinol with less than 2 mg/ml) among others such as terpenes and flavonoids, which gives rise to the name of the extraction and the designation “Full Spectrum” of this product.

>>> Join the Sechat group on WHATSAPP and receive the news first

Clinical studies show that Full Spectrum CBD plant extracts have an efficacy up to 3 times greater than Isolated CBD products because they more intensely and completely stimulate the cannabinoid receptors CB1 and CB2 in the body known as the “Entourage Effect.”

In addition to the well-documented use in the treatment of refractory epilepsy cases, CBD has shown promising results in treating conditions such as anxiety, insomnia, dementia, and autism, among others.

The product, which comes in a 10 ml bottle, will start being distributed at the end of May to pharmacies in the entire Southeast region of Brazil with a suggested retail price of R$379.

>>> Join the Sechat group on TELEGRAM and receive the news first

About Zion Med Pharma

Zion Med Pharma has among its founding partners and medical board Dr. Cláudio Lottenberg, an Ophthalmologist, president of the board of Hospital Albert Einstein and Chairman of the company, Dr. Dirceu Barbano, former president of Anvisa and Regulatory Affairs consultant, Dr. Luís Otávio Caboclo, a Neurologist and Professor at Albert Einstein College, and Lukas Johannes Fischer, Executive Director of the company.

“In this first year of operation, we will invest our energy mainly in disseminating the concept of the endocannabinoid system and the benefits of cannabinoids for the well-being and health of people, through continuous education programs and visits to the prescribing medical community,” emphasizes Lukas Fischer.

The company has established an important partnership agreement with Nestlé Health Science, one of the largest and most respected companies in the world, for medical visitation and training, with the aim of generating prescribing demand for phytotherapeutics and nutritional supplements throughout Brazil.

>>> Subscribe to our NEWSLETTER and receive reliable information from Sechat about Medical Cannabis

“Telemedicine is part of our strategy for practical access to digital medical prescriptions, providing access to our products with an agile online purchasing process and fast delivery with maximum convenience, to improve the quality of life of our patients,” adds Fischer, noting that it is still necessary to overcome some regulatory barriers to implement the digitization of this business model under RDC 327/19.

The company is currently seeking and analyzing potential partnerships for conducting clinical studies of other therapeutic indications for registration as a medicine with Anvisa.

“We have already started developing new cannabinoid formulations to expand our portfolio with even more competitive prices,” concludes Fischer, believing in strong growth and consolidation of the Medical Cannabis category, not only abroad but also in Brazil.

To learn more about Zion Med Pharma, visit: https://zionmedpharma.com.br/.